Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

医学 队列 病毒载量 安慰剂 内科学 临床终点 队列研究 外科 免疫学 人类免疫缺陷病毒(HIV) 临床试验 病理 替代医学
作者
Sorana Segal‐Maurer,Edwin DeJesus,Hans‐Jürgen Stellbrink,Antonella Castagna,Gary Richmond,Gary I. Sinclair,Krittaecho Siripassorn,Peter Ruane,Mezgebe Berhe,Hui Wang,Nicolas Margot,Hadas Dvory‐Sobol,Robert H. Hyland,Diana M. Brainard,Martin Rhee,Jared M. Baeten,Jean‐Michel Molina
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:386 (19): 1793-1803 被引量:107
标识
DOI:10.1056/nejmoa2115542
摘要

Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b study.In this phase 3 trial, we enrolled patients with multidrug-resistant HIV-1 infection in two cohorts, according to the change in the plasma HIV-1 RNA level between the screening and cohort-selection visits. In cohort 1, patients were first randomly assigned in a 2:1 ratio to receive oral lenacapavir or placebo in addition to their failing therapy for 14 days; during the maintenance period, starting on day 15, patients in the lenacapavir group received subcutaneous lenacapavir once every 6 months, and those in the placebo group received oral lenacapavir, followed by subcutaneous lenacapavir; both groups also received optimized background therapy. In cohort 2, all the patients received open-label oral lenacapavir with optimized background therapy on days 1 through 14; subcutaneous lenacapavir was then administered once every 6 months starting on day 15. The primary end point was the percentage of patients in cohort 1 who had a decrease of at least 0.5 log10 copies per milliliter in the viral load by day 15; a key secondary end point was a viral load of less than 50 copies per milliliter at week 26.A total of 72 patients were enrolled, with 36 in each cohort. In cohort 1, a decrease of at least 0.5 log10 copies per milliliter in the viral load by day 15 was observed in 21 of 24 patients (88%) in the lenacapavir group and in 2 of 12 patients (17%) in the placebo group (absolute difference, 71 percentage points; 95% confidence interval, 35 to 90). At week 26, a viral load of less than 50 copies per milliliter was reported in 81% of the patients in cohort 1 and in 83% in cohort 2, with a least-squares mean increase in the CD4+ count of 75 and 104 cells per cubic millimeter, respectively. No serious adverse events related to lenacapavir were identified. In both cohorts, lenacapavir-related capsid substitutions that were associated with decreased susceptibility developed in 8 patients during the maintenance period (6 with M66I substitutions).In patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo. (Funded by Gilead Sciences; CAPELLA ClinicalTrials.gov number, NCT04150068.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanmiao12完成签到,获得积分10
1秒前
香蕉觅云应助momo采纳,获得10
3秒前
4秒前
5秒前
爆米花应助李春鸿采纳,获得10
8秒前
LJJ发布了新的文献求助10
9秒前
10秒前
11秒前
12秒前
12秒前
Ava应助YYH采纳,获得10
12秒前
量子星尘发布了新的文献求助10
12秒前
小田心完成签到,获得积分10
12秒前
15秒前
小田心发布了新的文献求助10
15秒前
WYH发布了新的文献求助10
16秒前
一方通行发布了新的文献求助10
16秒前
SherlockHe发布了新的文献求助10
17秒前
FashionBoy应助热情的达采纳,获得10
17秒前
20秒前
lelelele发布了新的文献求助10
21秒前
拜拜完成签到,获得积分10
22秒前
22秒前
扶苏完成签到,获得积分10
22秒前
24秒前
mmm完成签到,获得积分20
25秒前
momo发布了新的文献求助10
25秒前
25秒前
一方通行完成签到,获得积分10
25秒前
xiaosu完成签到,获得积分10
26秒前
小马甲应助yyy采纳,获得10
29秒前
热情的达发布了新的文献求助10
29秒前
Hello应助任性的咖啡采纳,获得10
30秒前
30秒前
墨墨完成签到,获得积分10
30秒前
31秒前
cangy完成签到,获得积分10
32秒前
岸部完成签到,获得积分10
32秒前
在水一方应助WYH采纳,获得10
33秒前
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173